U.S. FDA approves Gilead's blood cancer drug Zydelig

July 23, 2014 4:06 PM

14 0

July 23 (Reuters) - The U.S. Food and Drug Administration has approved Gilead Inc's drug Zydelig to treat three types of blood cancer, the agency said on Wednesday.

The FDA approved it for use in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia.

Also read: FDA Approves First Nonopioid Treatment for Opioid Withdrawal Symptoms

Read more

To category page